Part, Chapter, Paragraph
1 I, 2. 8 | Nuclear~ ~Small risks from release of radioactive material,
2 II, 5. 5. 2| cross-border situations. Press release Available at: htt f (article
3 II, 5. 5. 3| Organization (2005b): Press release EURO/01/05; Copenhagen,
4 II, 5. 9. 4| chemical composition of PM on release of cytokines of cells in
5 II, 5. 11. 3| sweat corrosion are able to release metallic ions in the local
6 II, 5. 11. 3| the 0.5 µg Ni/cm2 /week release rate is likely not to protect
7 II, 5. 11. 3| at this level of nickel release, whilst the vast majority
8 II, 5. 11. 3| study on the content and the release of Ni and other allergenic
9 II, 6. 3. 7| potential for intentional release.~ ~In the last 10 years
10 II, 9. 5. 4| gender awareness. On their release in 2002, the FP6 framework
11 II, 9. 5. 6| the UK £15 billion. Press release: 16.06.05. Available at:~htt p~(
12 II, 9. 5. 6| the EU25. Eurostat News Release, 29/2006 - 6 March 2006~ ~
13 II, 9. 5. 6| responsibilities. Eurostat News Release. 169/2007 - 6 December 2007.
14 III, 10. 2. 1| body and causes a sudden release of glucose, as well as an
15 III, 10. 3. 2| PRTR~European Pollutant Release and Transfer~EUROSTAT~Statistical
16 III, 10. 3. 2| costs.~ ~ ~Emissions and release of chemicals are not only
17 III, 10. 3. 2| often associated to the release of high amounts of toxic
18 III, 10. 3. 2| following the accidental dioxin release in Seveso in 1976. The Seveso
19 III, 10. 4. 1| bacteria) but also increase the release of chemicals from construction
20 III, 10. 4. 2| degradation of polyacrylamide to release free monomeric acrylamide
21 III, 10. 4. 2| microorganisms;~· The experimental release of GMOs into the environment,
22 III, 10. 4. 2| EC (5) on the deliberate release into the environment of
23 III, 10. 4. 2| 18/EC on the deliberate release into the environment of
24 III, 10. 4. 2| 18/EC on the deliberate release of a GMO into the environment;~·
25 III, 10. 4. 2| March 2001 on the deliberate release into the environment of
26 IV, 11. 3. 2| governments purchase patents and release them for public use through
27 IV, 12. 5 | sources, including deliberate release acts; take action to ensure
28 IV, 12. 10 | Drug Coordinator (annually release, see www. e) and http / (
29 IV, 12. 10 | living conditions or after release assistance for maintenance